U.S. regulator says too many drugmakers chasing same cancer strategy
Friday, June 10, 2016 - 06:40
in Biology & Nature
CHICAGO (Reuters) - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach.